Scrip RSS Feedhttps://insights.citeline.comThe Latest News & Analysis from ScripWed, 22 Apr 2026 10:05:44 +0000en1hourly1 https://insights.citeline.com/scrip/r-and-d/clinical-trials/roche-upbeat-on-fenebrutinib-filing-prospects-despite-safety-questions-RRQ6HF6KY5DAHJHMNMPXH2VJ2A/<![CDATA[Roche Upbeat On Fenebrutinib Filing Prospects Despite Safety Questions]]>premium

      
]]> https://feeds.feedblitz.com/~/954197315/0/scrip~Roche-Upbeat-On-Fenebrutinib-Filing-Prospects-Despite-Safety-Questions/https://insights.citeline.com/scrip/r-and-d/clinical-trials/roche-upbeat-on-fenebrutinib-filing-prospects-despite-safety-questions-RRQ6HF6KY5DAHJHMNMPXH2VJ2A/
      
]]> Wed, 22 Apr 2026 00:00:00 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/merck-and-eisais-keytrudalenvimawelireg-trial-in-kidney-cancer-fails-4Y4GLHJNSNEKJEEHU4DP3SKAWI/<![CDATA[Merck And Eisai’s Keytruda/Lenvima/Welireg Trial In Kidney Cancer Fails ]]>premium

      
]]> https://feeds.feedblitz.com/~/954183611/0/scrip~Merck-And-Eisai%e2%80%99s-KeytrudaLenvimaWelireg-Trial-In-Kidney-Cancer-Fails/https://insights.citeline.com/scrip/r-and-d/clinical-trials/merck-and-eisais-keytrudalenvimawelireg-trial-in-kidney-cancer-fails-4Y4GLHJNSNEKJEEHU4DP3SKAWI/
      
]]> Tue, 21 Apr 2026 20:09:18 +0000 https://insights.citeline.com/scrip/therapeutic-category/cardiovascular/bioage-outlines-clinical-expansion-plans-for-bge-102-G3EBRD5MCRC35FFYPRDOAQNEHQ/<![CDATA[BioAge Outlines Clinical Expansion Plans For BGE-102 ]]>premium

      
]]> https://feeds.feedblitz.com/~/954184082/0/scrip~BioAge-Outlines-Clinical-Expansion-Plans-For-BGE/https://insights.citeline.com/scrip/therapeutic-category/cardiovascular/bioage-outlines-clinical-expansion-plans-for-bge-102-G3EBRD5MCRC35FFYPRDOAQNEHQ/
      
]]> Tue, 21 Apr 2026 20:29:15 +0000 https://insights.citeline.com/scrip/market-access/bayer-pledges-loyalty-to-europe-but-demands-more-support-PPRC2JGNQNAHPL6PHEUNUHUJLY/<![CDATA[Bayer Pledges Loyalty To Europe But Demands More Support ]]>premium

      
]]> https://feeds.feedblitz.com/~/954164399/0/scrip~Bayer-Pledges-Loyalty-To-Europe-But-Demands-More-Support/https://insights.citeline.com/scrip/market-access/bayer-pledges-loyalty-to-europe-but-demands-more-support-PPRC2JGNQNAHPL6PHEUNUHUJLY/
      
]]> Tue, 21 Apr 2026 15:10:50 +0000 https://insights.citeline.com/scrip/market-intelligence/top-drugs/top-10-drugs-2025-keytruda-holds-the-crown-but-tirzepatide-is-coming-7S6K7VKWNZDSLO32N4S5H2YS6I/<![CDATA[Top 10 Drugs 2025: Keytruda Holds The Crown, But Tirzepatide Is Coming]]>premium

      
]]> https://feeds.feedblitz.com/~/954164402/0/scrip~Top-Drugs-Keytruda-Holds-The-Crown-But-Tirzepatide-Is-Coming/https://insights.citeline.com/scrip/market-intelligence/top-drugs/top-10-drugs-2025-keytruda-holds-the-crown-but-tirzepatide-is-coming-7S6K7VKWNZDSLO32N4S5H2YS6I/
      
]]> Tue, 21 Apr 2026 14:59:34 +0000 https://insights.citeline.com/scrip/business/stock-watch/stock-watch-prospects-for-peace-help-jj-after-results-announcement-5FM574I6P5EIJC4UWE5LQS2ZVQ/<![CDATA[Stock Watch: Prospects For Peace Help J&J After Results Announcement]]>premium

      
]]> https://feeds.feedblitz.com/~/954152120/0/scrip~Stock-Watch-Prospects-For-Peace-Help-JJ-After-Results-Announcement/https://insights.citeline.com/scrip/business/stock-watch/stock-watch-prospects-for-peace-help-jj-after-results-announcement-5FM574I6P5EIJC4UWE5LQS2ZVQ/
      
]]> Tue, 21 Apr 2026 12:09:29 +0000 https://insights.citeline.com/scrip/focus-on-asia/india/indias-trademark-regime-regulatory-gaps-patient-safety-risks-and-criminal-contempt-M2G2JP7O4VHFVGCK6V2433DNTM/<![CDATA[India’s Trademark Regime: Regulatory Gaps, Patient Safety Risks And ‘Criminal Contempt’ ]]>premium

      
]]> https://feeds.feedblitz.com/~/954157844/0/scrip~India%e2%80%99s-Trademark-Regime-Regulatory-Gaps-Patient-Safety-Risks-And-%e2%80%98Criminal-Contempt%e2%80%99/https://insights.citeline.com/scrip/focus-on-asia/india/indias-trademark-regime-regulatory-gaps-patient-safety-risks-and-criminal-contempt-M2G2JP7O4VHFVGCK6V2433DNTM/
      
]]> Tue, 21 Apr 2026 13:29:55 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/astrazenecas-ultomiris-hits-interim-phase-iii-endpoint-in-igan-eyes-accelerated-filings-PYPAM2WS35BTHKUAMCTFJCBPXA/<![CDATA[AstraZeneca’s Ultomiris Hits Interim Phase III Endpoint In IgAN, Eyes Accelerated Filings]]>premium

      
]]> https://feeds.feedblitz.com/~/954161735/0/scrip~AstraZeneca%e2%80%99s-Ultomiris-Hits-Interim-Phase-III-Endpoint-In-IgAN-Eyes-Accelerated-Filings/https://insights.citeline.com/scrip/r-and-d/clinical-trials/astrazenecas-ultomiris-hits-interim-phase-iii-endpoint-in-igan-eyes-accelerated-filings-PYPAM2WS35BTHKUAMCTFJCBPXA/
      
]]> Tue, 21 Apr 2026 14:34:44 +0000 https://insights.citeline.com/scrip/therapeutic-category/neurological/xenons-azetukalner-confirms-phase-iii-efficacy-signal-sets-up-mid-year-nda-filing-LMWTN7E62FHT5KXGGZIVSX4FYU/<![CDATA[Xenon’s Azetukalner Confirms Phase III Efficacy Signal, Sets Up Mid-Year NDA Filing]]>premium

      
]]> https://feeds.feedblitz.com/~/954146126/0/scrip~Xenon%e2%80%99s-Azetukalner-Confirms-Phase-III-Efficacy-Signal-Sets-Up-MidYear-NDA-Filing/https://insights.citeline.com/scrip/therapeutic-category/neurological/xenons-azetukalner-confirms-phase-iii-efficacy-signal-sets-up-mid-year-nda-filing-LMWTN7E62FHT5KXGGZIVSX4FYU/
      
]]> Tue, 21 Apr 2026 09:23:17 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/nektar-charts-rezpegs-late-stage-development-in-alopecia-areata-on-long-term-phase-ii-data-GQIQFRRLZJAC7AAWKLZHQZWXHM/<![CDATA[Nektar Charts Rezpeg’s Late-Stage Development In Alopecia Areata On Long Term Phase II Data]]>premium

      
]]> https://feeds.feedblitz.com/~/954150701/0/scrip~Nektar-Charts-Rezpeg%e2%80%99s-LateStage-Development-In-Alopecia-Areata-On-Long-Term-Phase-II-Data/https://insights.citeline.com/scrip/r-and-d/clinical-trials/nektar-charts-rezpegs-late-stage-development-in-alopecia-areata-on-long-term-phase-ii-data-GQIQFRRLZJAC7AAWKLZHQZWXHM/
      
]]> Tue, 21 Apr 2026 11:28:20 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/argenx-shows-deepening-responses-for-vyvgart-across-the-mg-spectrum-U2YW3PVX5VDCPDOBJADCXFNJQU/<![CDATA[Argenx Shows Deepening Responses For Vyvgart Across The MG Spectrum ]]>premium

      
]]> https://feeds.feedblitz.com/~/954145514/0/scrip~Argenx-Shows-Deepening-Responses-For-Vyvgart-Across-The-MG-Spectrum/https://insights.citeline.com/scrip/r-and-d/clinical-trials/argenx-shows-deepening-responses-for-vyvgart-across-the-mg-spectrum-U2YW3PVX5VDCPDOBJADCXFNJQU/
      
]]> Tue, 21 Apr 2026 09:20:16 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/aacr-hansohs-adc-impresses-in-io-combo-for-2l-nsclc-UCFI2OOJDJCNTDYVAHQXYEO75Q/<![CDATA[AACR: Hansoh’s ADC Impresses In IO Combo For 2L NSCLC]]>premium

      
]]> https://feeds.feedblitz.com/~/954140681/0/scrip~AACR-Hansoh%e2%80%99s-ADC-Impresses-In-IO-Combo-For-L-NSCLC/https://insights.citeline.com/scrip/r-and-d/clinical-trials/aacr-hansohs-adc-impresses-in-io-combo-for-2l-nsclc-UCFI2OOJDJCNTDYVAHQXYEO75Q/
      
]]> Tue, 21 Apr 2026 06:49:47 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/could-pd-l1vegf-agents-face-off-first-in-china-phase-iii-trials-2G3GAKRRENGN3FTPN5NH4YAMAY/<![CDATA[Could PD-(L)1/VEGF Agents Face Off First In China Phase III Trials?]]>premium

      
]]> https://feeds.feedblitz.com/~/954131867/0/scrip~Could-PDLVEGF-Agents-Face-Off-First-In-China-Phase-III-Trials/https://insights.citeline.com/scrip/r-and-d/clinical-trials/could-pd-l1vegf-agents-face-off-first-in-china-phase-iii-trials-2G3GAKRRENGN3FTPN5NH4YAMAY/
      
]]> Tue, 21 Apr 2026 03:06:51 +0000 https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KROBJCLAKVFBLCZ7BGBGCE3VDQ/<![CDATA[Quick Listen: Scrip’s Five Must-Know Things]]>free

      
]]> https://feeds.feedblitz.com/~/954129323/0/scrip~Quick-Listen-Scrip%e2%80%99s-Five-MustKnow-Things/https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KROBJCLAKVFBLCZ7BGBGCE3VDQ/
      
]]> Tue, 21 Apr 2026 01:44:45 +0000 https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-seven-approvals-and-a-phase-iii-readout-EJT4GEC4EZEHPC3ZSY6XYVZUOA/<![CDATA[Pipeline Watch: Seven Approvals And A Phase III Readout]]>premium

      
]]> https://feeds.feedblitz.com/~/954096926/0/scrip~Pipeline-Watch-Seven-Approvals-And-A-Phase-III-Readout/https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-seven-approvals-and-a-phase-iii-readout-EJT4GEC4EZEHPC3ZSY6XYVZUOA/
      
]]> Mon, 20 Apr 2026 13:01:07 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/astrazeneca-builds-copd-case-for-tozorakimab-with-third-positive-phase-iii-trial-BETMCN7AVNFV5KK5INJB7QYJ7M/<![CDATA[AstraZeneca Builds COPD Case For Tozorakimab With Third Positive Phase III Trial]]>premium

      
]]> https://feeds.feedblitz.com/~/954096050/0/scrip~AstraZeneca-Builds-COPD-Case-For-Tozorakimab-With-Third-Positive-Phase-III-Trial/https://insights.citeline.com/scrip/r-and-d/clinical-trials/astrazeneca-builds-copd-case-for-tozorakimab-with-third-positive-phase-iii-trial-BETMCN7AVNFV5KK5INJB7QYJ7M/
      
]]> Mon, 20 Apr 2026 12:30:40 +0000 https://insights.citeline.com/scrip/business/strategy/fresh-off-phase-iii-revolution-presents-positive-frontline-daraxonrasib-data-WFQ3JHMFS5H5PD4ETE4JG3QDSA/<![CDATA[Fresh Off Phase III, Revolution Presents Positive Frontline Daraxonrasib Data]]>premium

      
]]> https://feeds.feedblitz.com/~/954113438/0/scrip~Fresh-Off-Phase-III-Revolution-Presents-Positive-Frontline-Daraxonrasib-Data/https://insights.citeline.com/scrip/business/strategy/fresh-off-phase-iii-revolution-presents-positive-frontline-daraxonrasib-data-WFQ3JHMFS5H5PD4ETE4JG3QDSA/
      
]]> Mon, 20 Apr 2026 18:28:42 +0000 https://insights.citeline.com/scrip/therapeutic-category/blood-and-clotting/novo-nordisk-shows-sickle-cell-efficacy-advantage-over-agioss-mitapivat-IHLWRLHPMJC4JO2INPJJZYI7YM/<![CDATA[Novo Nordisk Shows Sickle Cell Efficacy Advantage Over Agios’s Mitapivat ]]>premium

      
]]> https://feeds.feedblitz.com/~/954117065/0/scrip~Novo-Nordisk-Shows-Sickle-Cell-Efficacy-Advantage-Over-Agios%e2%80%99s-Mitapivat/https://insights.citeline.com/scrip/therapeutic-category/blood-and-clotting/novo-nordisk-shows-sickle-cell-efficacy-advantage-over-agioss-mitapivat-IHLWRLHPMJC4JO2INPJJZYI7YM/
      
]]> Mon, 20 Apr 2026 20:08:46 +0000 https://insights.citeline.com/scrip/business/deals/lilly-adds-to-in-vivo-car-t-capabilities-with-kelonia-buyout-7PFEOZOPOVBTPGZCXCXGUYHYFI/<![CDATA[Lilly Adds To In Vivo CAR-T Capabilities With Kelonia Buyout]]>premium

      
]]> https://feeds.feedblitz.com/~/954121580/0/scrip~Lilly-Adds-To-In-Vivo-CART-Capabilities-With-Kelonia-Buyout/https://insights.citeline.com/scrip/business/deals/lilly-adds-to-in-vivo-car-t-capabilities-with-kelonia-buyout-7PFEOZOPOVBTPGZCXCXGUYHYFI/
      
]]> Mon, 20 Apr 2026 21:58:35 +0000 https://insights.citeline.com/scrip/r-and-d/boehringer-ingelheims-ai-investment-is-welcome-news-for-the-uk-EY2OFNRCDBDGTFTWOGW3PA3YKY/<![CDATA[Boehringer Ingelheim’s AI Investment Is Welcome News For The UK]]>premium

      
]]> https://feeds.feedblitz.com/~/954109541/0/scrip~Boehringer-Ingelheim%e2%80%99s-AI-Investment-Is-Welcome-News-For-The-UK/https://insights.citeline.com/scrip/r-and-d/boehringer-ingelheims-ai-investment-is-welcome-news-for-the-uk-EY2OFNRCDBDGTFTWOGW3PA3YKY/
      
]]> Mon, 20 Apr 2026 16:58:08 +0000 https://insights.citeline.com/scrip/leadership/interviews/alphamab-pursues-differentiated-approach-to-next-gen-adcs-455SCBRW4JFKNB2PVPAHV473XU/<![CDATA[Alphamab Pursues Differentiated Approach To Next-Gen ADCs]]>premium

      
]]> https://feeds.feedblitz.com/~/954084275/0/scrip~Alphamab-Pursues-Differentiated-Approach-To-NextGen-ADCs/https://insights.citeline.com/scrip/leadership/interviews/alphamab-pursues-differentiated-approach-to-next-gen-adcs-455SCBRW4JFKNB2PVPAHV473XU/
      
]]> Mon, 20 Apr 2026 07:53:22 +0000